Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Ingelheim Expands License for Spotfire s DecisionSite

NEW YORK, Sept. 27 (GenomeWeb News) - Spotfire said today that Boehringer Ingelheim will deploy its DecisionSite software worldwide across its R&D activities.


The agreement extends a narrower licensing agreement that Boehringer Ingelheim has had with Spotfire since 1997 to use the software in genomics, lead discovery, and medicinal chemistry.


Under the global agreement, the company will deploy DecisionSite across its research organization, from target discovery through pre-clinical research, in Germany, Austria, Italy, Canada, and the United States.


Financial terms of the agreement were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.